Cover ImageSALE
市場調查報告書

核酸檢驗的全球市場:2016∼2020年

Global Nucleic Acid Testing Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 407975
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
核酸檢驗的全球市場:2016∼2020年 Global Nucleic Acid Testing Market 2016-2020
出版日期: 2016年12月01日 內容資訊: 英文 79 Pages
簡介

核酸檢驗是個人的血液樣品的病毒DNA及RNA的檢測相關的流程。核酸增幅檢查是體外診斷市場上最快成長的市場區隔之一。全球核酸檢驗市場,預計從2016年到2020年以9.96%的年複合成長率擴大。

本報告提供全球核酸檢驗市場的相關調查,市場現狀與未來發展預測,各分類市場趨勢,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 各產品市場區隔

  • 設備
  • 試劑

第7章 各適應症市場區隔

  • 市場概要
  • 感染疾病
  • 癌症
  • 遺傳基因

第8章 各技術市場區隔

  • 聚合酵素鏈鎖反應(PCR)
  • DNA鎖鏈置換放大(SDA)
  • 連結?鏈反應(LCR)
  • 其他

第9章 各終端用戶市場區隔

  • 醫院
  • 診療所
  • 研究機關

第10章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區市場

第11章 推動市場的要素

第12章 促進要素的影響

第13章 市場課題

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式

第17章 主要供應商分析

  • Abbott Laboratories
  • Roche Molecular Systems
  • Siemens Healthineers
  • Hologic
  • Qiagen
  • 關注企業
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

圖表

目錄
Product Code: IRTNTR10992

About Nucleic Acid Testing

Nucleic acid testing (NAT) is the process involved in the detection of viral DNAs and RNAs in blood samples of individuals. NAT or nucleic acid amplification test (NAAT) is one of the fastest growing segments in the in-vitro diagnostics market (IVD). There are different types of NAT techniques such as Polymerase chain reaction (PCR), Strand displacement amplification (SDA), Ligase chain reaction (LCR), Transcription-mediated amplification (TMA), Nucleic acid sequence based amplification (NASBA) and whole genome sequencing.

Technavio's analysts forecast the global nucleic acid testing market to grow at a CAGR of 9.96% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global nucleic acid testing market for 2016-2020. To calculate the market size, the report presents the vendor landscape and a corresponding detailed analysis of the top vendors operating in the market.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Nucleic Acid Testing Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Abbott Laboratories
  • Roche Molecular Systems
  • Siemens Healthineers
  • Hologic
  • Qiagen

Other Prominent Vendors

  • Accriva Diagnostics
  • Acon Laboratories
  • Affymetrix
  • Ahram Biosystem
  • Asuragen
  • Biocartis
  • Bio-Rad Laboratories
  • Cepheid
  • DiagCor
  • EKF Diagnostics
  • Erba Diagnostics
  • Randox Laboratories

Market driver

  • Higher adoption rate of molecular point-of-care (POC) testing.
  • For a full, detailed list, view our report

Market challenge

  • Risks associated with molecular diagnosis.
  • For a full, detailed list, view our report

Market trend

  • Advances in precision and personalized medicine.
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by product

  • Instruments
  • Reagents

PART 07: Market segmentation by indication

  • Market overview
  • Infectious diseases
  • Cancer
  • Genetics

PART 08: Market segmentation by technology

  • Polymerase chain reaction (PCR)
  • Strand displacement amplification (SDA)
  • Ligase chain reaction (LCR)
  • Others

PART 09: Market segmentation by end-users

  • Hospitals
  • Clinics
  • Research institutes

PART 10: Geographical segmentation

  • Nucleic acid testing market in Americas
  • Nucleic acid testing market in the EMEA
  • Nucleic acid testing market in the APAC

PART 11: Market drivers

  • Genome engineering and gene editing on rise
  • Higher adoption rate of molecular point-of-care (POC) testing
  • Improved sensitivity for the detection systems

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of equipment and reagents
  • Stringent regulatory framework
  • Risks associated with molecular diagnosis

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Next generation sequencing
  • Higher adoption rate for NAT
  • Advances in precision and personalized medicine

PART 16: Vendor landscape

  • Competitive scenario

PART 17: Key vendor analysis

  • Abbott Laboratories
  • Roche Molecular Systems
  • Siemens Healthineers
  • Hologic
  • Qiagen
  • Key Companies to watch
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global nucleic acid testing market 2015-2020 ($ billions)
  • Exhibit 03: Global nucleic acid testing market diversification
  • Exhibit 04: Impact assessment for global nucleic acid testing market
  • Exhibit 05: Five forces analysis
  • Exhibit 06: Global nucleic acid testing market by product 2015-2020 (%)
  • Exhibit 07: Global nucleic acid testing market segmentation
  • Exhibit 08: Global nucleic acid testing market by indication 2015-2020 (%)
  • Exhibit 09: NAT tests for infectious diseases
  • Exhibit 10: Nucleic acid testing market by indication - infectious diseases 2015-2020 ($ billion)
  • Exhibit 11: Nucleic acid testing market by indication - cancer 2015-2020 ($ billions)
  • Exhibit 12: Nucleic acid testing market by indication - genetics 2015-2020 ($ billions)
  • Exhibit 13: Global nucleic acid testing market by technology 2015-2020 (%)
  • Exhibit 14: Market strategy analysis of PCR technology
  • Exhibit 15: Market dynamics of PCR technology
  • Exhibit 16: Market strategy analysis of SDA technology
  • Exhibit 17: Market dynamics of SDA technology
  • Exhibit 18: Market strategy analysis of LCR technology
  • Exhibit 19: Market dynamics of LCR technology
  • Exhibit 20: Global nucleic acid testing market by end-users 2015-2020 (%)
  • Exhibit 21: Market overview of nucleic acid testing in Americas
  • Exhibit 22: Nucleic acid testing market in Americas 2015-2020 ($ billions)
  • Exhibit 23: Market overview of nucleic acid testing in EMEA
  • Exhibit 24: Nucleic acid testing market in EMEA 2015-2020 ($ billions)
  • Exhibit 25: Market overview of nucleic acid testing in APAC
  • Exhibit 26: Nucleic acid testing market in APAC 2015-2020 ($ billions)
  • Exhibit 27: Impact of drivers
  • Exhibit 28: Market impact of regulatory policies in different countries
  • Exhibit 29: Impact of drivers and challenges
  • Exhibit 30: Common methods in next generation sequencing
  • Exhibit 31: Key application areas of next generation sequencing technology
  • Exhibit 32: Comparison between NAT and serological blood screening
  • Exhibit 33: Features and benefits of personalized medicines - Market impact
  • Exhibit 34: Competitive structure analysis of global nucleic acid testing market 2015
  • Exhibit 35: Market penetration of global nucleic acid testing manufacturers (2015)
  • Exhibit 36: Strategic success factors of companies in global nucleic acid testing market
  • Exhibit 37: Abbott Laboratories strength assessment
  • Exhibit 38: Abbott Laboratories strategy assessment
  • Exhibit 39: Abbott Laboratories opportunity assessment
  • Exhibit 40: Roche Molecular Systems strength assessment
  • Exhibit 41: Roche Molecular Systems strategy assessment
  • Exhibit 42: Roche Molecular Systems: Opportunity assessment
  • Exhibit 43: Siemens Healthineers strength assessment
  • Exhibit 44: Siemens Healthineers strategy assessment
  • Exhibit 45: Siemens Healthineers: Opportunity assessment
  • Exhibit 46: Hologic strength assessment
  • Exhibit 47: Hologic strategy assessment
  • Exhibit 48: Hologic: Opportunity assessment
  • Exhibit 49: Qiagen strength assessment
  • Exhibit 50: Qiagen strategy assessment
  • Exhibit 51: Qiagen: Opportunity assessment
Back to Top